Table 1.

PDE2 inhibitors studied.

Comp.#	pIC 50 a	n b	R	W	X	Y	Z
2	8.57 ± 0.15	8	H	H	Cl	C	H
4	8.14 ± 0.30	13	OBu	H	H	N	H
6	8.02 ± 0.20	5	H	H	Cl	C	F
7	8.71 ± 0.19	13	H	F	Cl	C	H
8	7.59 ± 0.23	3	H	H	Me	N	H
9	8.22 ± 0.30	9	OMe	H	Cl	C	H
10	7.92 ± 0.08	3	OMe	H	H	N	H
11	8.21 ± 0.21	4	OEt	H	Cl	C	H
12	7.37 ± 0.20	3	OEtF	H	H	N	H
13	8.19 ± 0.17	4	OPr	H	Cl	C	H
14	7.52 ± 0.16	5	OPr	H	H	N	H
15	8.75 ± 0.36	6	OiPr	H	Cl	C	H
16	6.42 ± 0.13	6	OiPr	H	H	N	H
17	7.53 ± 0.15	3	MeOEt	H	H	N	H
18	7.05 ± 0.25	7	EtOMe	H	H	N	H
19	7.19 ± 0.01	2	OPrF	H	H	N	H
20	7.0 ± 0.19	5	OEtOMe	H	H	N	H
21	8.1 ± 0.22	8	OBu	H	Cl	C	H
22	6.93 ± 0.05	2	OBu	H	H	N	Cl
23	6.88 ± 0.31	2	PrOMe	H	H	N	H
24	7.85 ± 0.30	8	OMe-cycloPr	H	H	N	H

^aErrors are standard deviations. ^bn refers to number of independent repeat experimental measurements of pIC₅₀, each repeat was performed in triplicate. The small compounds were: 2, 6, 7, 8, 9, and 10, and the large compounds were: 4, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 and 24.